NEW YORK--(BUSINESS WIRE)--Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced receipt of a signed trial agreement from the Queen’s Medical Center in Honolulu, Hawaii for its second Blood Volume Analyzer. Queen’s Medical Center, which purchased its first BVA-100 following a trial agreement, utilized blood volume measurements for various clinical applications. This second BVA-100 will be utilized specifically for treating blood volume derangements in the critical care unit. Queens is the first medical center to utilize two blood volume analyzers.
